ORAMED PHARMACEUTICALS INC. Interest Expense
ORAMED PHARMACEUTICALS INC. (ORMP) reported Interest Expense of $592.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-09
- ORAMED PHARMACEUTICALS INC. interest expense for the quarter ending 2024-03-31 was $592.00K.
- ORAMED PHARMACEUTICALS INC. interest expense for the quarter ending 2023-12-31 was $1.21M.
- ORAMED PHARMACEUTICALS INC. interest expense for the quarter ending 2023-09-30 was $826.00K.
- ORAMED PHARMACEUTICALS INC. interest expense for fiscal 2023 was $2.04M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $592.00K 10-Q · filed 2024-05-09 | $1.80M derived: sum of 2 quarters · filed 2024-05-09 | $2.63M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2023-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $2.04M derived: sum of 2 quarters · filed 2024-03-06 | $2.04M 10-K · filed 2024-03-06 | |
| 2023-09-30 | $826.00K 10-Q · filed 2023-11-09 | $826.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |